Probiotics, with special emphasis on their role in the management of irritable bowel syndrome

References

• Metchnikoff E. The prolongation of life: optimistic studies. London: Butterworth-Heinemann; 1907.
   Google Scholar
• Rijkers GT. Guidance for substantiating the evidence for beneficial effects of probiotics: current status and recommendations for future research. J Nutr. 2010;140:671S–76S.
   Google Scholar
• FAO/WHO. Joint FAO/WHO expert consultation on evaluation of health and nutritional properties in food including powder milk with live lactic acid bacteria. Health and nutritional properties of probiotics in foods including powder milk with live lactic acid bacteria [homepage on the Internet]. Available from: http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf
   Google Scholar
• Sanders ME. How do we know when something called “probiotic” is really a probiotic? A guideline for consumers and health care professionals. Functional Food Rev. 2009;1:3–12.
   Google Scholar
• Douglas LC, Sanders ME. Probiotics and prebiotics in dietetics practice. J Am Diet Assoc. 2008;108:510–521.
   Google Scholar
• Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol. 1996;4:430–435.
   Google Scholar
• Abt MC, Artis D. The intestinal microbiota in health and disease: the influence of microbial products on immune cell homeostasis. Curr Opin Gastroenterol. 2009;25:496–502.
   Google Scholar
• Ley RE, Peterson DA, Gordan JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124:837–848.
   Google Scholar
• Chen J, Cai W, Feng Y. Development of intestinal bifidobacteria and lactobacilli in breast-fed neonates. Clin Nutr. 2007;26:559–566.
   Google Scholar
• Conroy ME, Shi HN, Walker WA. The long-term health effects of neonatal microbial flora. Curr Opin Allergy Clin Immunol. 2009;9:197–201.
   Google Scholar
• Taylor SN, Basile LA, Ebeling M, Wagner CL. Intestinal permeability in preterm infants by feeding type: mother’s milk versus formula. Breastfeed Med. 2009;4:11–15.
   Google Scholar
• Vael C, Desager K. The importance of the development of the intestinal microbiota in infancy. Curr Opin Pediat. 2009;21:794–800.
   Google Scholar
• Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2010;7:503–514.
   Google Scholar
• Brackmann S, Aamodt G, Andersen SN, et al. Widespread but not localised neoplasia in inflammatory bowel disease worsens the prognosis of colorectal cancer. Inflamm Bowel Dis. 2009;16(3):474–481.
   Google Scholar
• Atarashi K, Nishimura J, Shima T, et al. ATP drives lamina propria T (H) 17 cell differentiation. Nature. 2008;455(2714):808–812.
   Google Scholar
• Ivanov II, Frutos Rde L, Manel N, et al. Specific microbiota direct the differentiation of IL-17 producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 2008;4(4):337–349.
   Google Scholar
• Ley RE, Turnbaugh PJ. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022–1023.
   Google Scholar
• Turnbaugh PJ, Ley RE. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–1031.
   Google Scholar
• Karin M, Lawrence T. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006;124:823–835.
   Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
   Google Scholar
• Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53:685–693.
   Google Scholar
• Kassinen A, Krogius-Kurikka L, Mäkivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133(1):24–33.
   Google Scholar
• Balsari A. The fecal microbial population in the irritable bowel syndrome. Microbiology. 1982;5:185–194.
   Google Scholar
• Bayliss CE, Houstan AP. Microbiological studies on food intolerance. Proc Nutr Soc. 1984;43(1):16A.
   Google Scholar
• Bradley HK, Wyatt GM. Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol. 1987;23:29–32.
   Google Scholar
• Malinen E, Rinttilä T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol. 2005;100:373–382.
   Google Scholar
• Tannock GW. Molecular analysis of the intestinal microflora in IBD. Mucosal Immunol 2008;1(Suppl 1):S15-S18.
   Google Scholar
• Swidsinski A, Loening-Baucke V, Verstraelen H, et al. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology. 2008;135:568–579.
   Google Scholar
• Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr. 1999;69:1035S–1045S.
   Google Scholar
• Jonkers D, Stockbrügger R. Review article: probiotics in gastrointestinal and liver disease. Aliment Pharmacol Ther. 2007;26(Suppl 2):133–148.
   Google Scholar
• Floch MH, Walker WA, Guandalini S, et al. Recommendations for probiotic use: 2008. J Clin Gastroenterol. 2008;42(Suppl 2):S104-S108.
   Google Scholar
• Tennyson CA, Friedman G. Microecology, obesity and probiotics. Current opinion in endocrinology. Diabetes Obes. 2008;15:422–427.
   Google Scholar
• Roberfroid M. Functional food concept and its application to prebiotics. Dig Liver Dis. 2002;34(Suppl 2):S105-S110.
   Google Scholar
• Brouns F, Kettlitz B, Arrigoni E. Resistant starch and the butyrate revolution. Trends Food Sci Technol. 2002;13:251–261.
   Google Scholar
• Edwards CA, Parrett AM. Intestinal flora during the first months of life: new perspectives. Br J Nutr. 2002;88(Suppl 1):S11-S18.
   Google Scholar
• Biorivant M, Strober W. The mechanism of action of probiotics. Curr Opin Gastroenterol. 2007;23:679–692.
   Google Scholar
• Fujiya M, Kohgo Y. Novel perspectives in probiotic treatment: the efficacy and unveiled mechanisms of the physiological functions. Clin J Gastroenterol. 2010;3:117–127.
   Google Scholar
• Spiller R. Review article: probiotics and prebiotcs in irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28:385–396.
   Google Scholar
• Broekaert IL, Walker WA. Probiotics and chronic disease. J Clin Gastroenterol. 2006;40:270–274.
   Google Scholar
• Brenner DM, Moeller MJ. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009:104:1033–1049.
   Google Scholar
• Sanders ME. Probiotics: definition, sources, selection and uses. Clin Infect Dis. 2008;46(Suppl 2):S58-S61.
   Google Scholar
• Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101:1581–1590.
   Google Scholar
• Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108–114.
   Google Scholar
• Adams CA. The probiotic paradox: live and dead cells are biological response modifiers. Nutr Res Rev. 2010;23(1):37–46.
   Google Scholar
• Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomized, double-blind, placebo controlled trial. Lancet. 2008;371:651–659.
   Google Scholar
• Oláh A, Belágyi T, Pótó L, et al. Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. Hepatogastroenterology. 2007;54(74):590–594.
   Google Scholar
• Whelan K, Myers CE. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. Am J Clin Nutr. 2010;91:687–703.
   Google Scholar
• Boyle RJ, Robins-Browne J, Tang MLK. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006 83:1256–1264.
   Google Scholar
• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.
   Google Scholar
• McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008;14(17):2650–2661.
   Google Scholar
• Horwitz B, Fisher RS. Current concepts: the irritable bowel syndrome. N Engl J Med. 2001;344:1846–1850.
   Google Scholar
• Verdu EF, Collins SM. Irritable bowel syndrome and probiotics: from rationale to clinical use. Curr Opin Gastroenterol. 2005;21:697–701.
   Google Scholar
• Cabre E. Irritable bowel syndrome: can nutrient manipulation help? Curr Opin Clin Nutr Metab Care. 2010;13:581–587.
   Google Scholar
• Dinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 2006:130:304–311.
   Google Scholar
• Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007:132:913–920.
   Google Scholar
• O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;53:281–288.
   Google Scholar
• Harris LR, Roberts L. Treatments for irritable bowel syndrome: patients’ attitudes and acceptability. BMC Complement Altern Med. 2008;19(8):65.
   Google Scholar
• Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, et al. Design of treatment trials for functional gastrointestinal disorders. Gut. 1999;45(Suppl II):1169–1177.
   Google Scholar
• Mouyyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325–332.
   Google Scholar
• McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202–2222.
   Google Scholar
• Hoveyda N, Heneghan C, Mahtani KR, et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol. 2009;9:15.
   Google Scholar
• Nikfar S, Rahimi R, Rahimi F, et al. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum. 2008;51(12):1775–1780.
   Google Scholar
• Andruilli A, Neri M, Loguercio C, et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multi-center, randomized study. J Clin Gastroenterol. 2008;42(Suppl 3, Pt 2):S218-S23.
   Google Scholar
• Bittner AC, Croffut RM, Stranahan MC. Prescript-assist probiotic–prebiotic treatment for irritable bowel syndrome: a methodologically orientated, 2-week, randomized, placebo-controlled, double-blind clinical study. Clin Ther. 2005;27:755–761.
   Google Scholar
• Zeng J, Li YQ, Zuo XL, et al. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28:994–1002.
   Google Scholar
• Tsuchiya J, Barreto R, Okura R, et al. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis. 2004;5:169–174.
   Google Scholar
• Barrett JS, Canale KE, Gearry RB, et al. Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World J Gastroenterol. 2008;14:5020–5024.
   Google Scholar
• Bausserman M, Michail S. The use of lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized controlled trial. J Pediatr. 2005;147:197–201.
   Google Scholar
• Gawronska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacilli GG for abdominal pain disorders in children. Aliment Pharmacol Ther. 2007;25:177–184.
   Google Scholar
• O’Sullivan MA, O’Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomized placebo-controlled crossover study. Digest Liv Dis. 2000;32:284–301.
   Google Scholar
• Nobaek S, Johansson ML. Alteration of intestinal microflora associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000;95(5):1231–1238.
   Google Scholar
• Niedzielin K, Kordecki H. A controlled double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2001;13:1143–1147.
   Google Scholar
• Sen S, Mullan MM. Effect of Lactobacillus plantarum 299V on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci. 2002;47:2615–2620.
   Google Scholar
• Kim HJ, Camilleri M, McKenzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:895–904.
   Google Scholar
• Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005;17:687–696.
   Google Scholar
• Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol .2004;38(Suppl 6):S104-S106.
   Google Scholar
• Kajander K, Krogius-Kurikka L. Effects of multi-species probiotc supplementation on intestinal microbiota in irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26(3):463–473.
   Google Scholar
• Lyra A, Krogius-Kurikka L, Nikkilä J, et al. Effect of a multi-species probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. BMC Gastroenterol. 2010;10:110.
   Google Scholar
• Kajander K, Myllyluoma E, Rajilić-Stojanović M, et al. Clinical trial: multi-species probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilises intestinal microbiota. Aliment Pharmacol Ther. 2008;27:48–57.
   Google Scholar
• Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome: a double blind, placebo-controlled, randomized study. Clin Nutr. 2005;24:925–931.
   Google Scholar
• Guyonnet D, Chassany O, Ducrotte P, et al. Effect of fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multi-center, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 2007;26:475–486.
   Google Scholar
• Drouault-Holowacz S, Bieuvelet S, Burckel A, et al. A double-blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol. 2008;32(2):147–152.
   Google Scholar
• Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distention and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2009;29:101–114.
   Google Scholar
• Sinn DH, Song JH, Kim HJ, et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci. 2008;53:2714–2718.
   Google Scholar
• Enck P, Zimmerman K, Menke G, et al. A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome: a randomized controlled trial with primary care physicians. Neurogastroenterol Motil. 2008;20:1103–1109.
   Google Scholar
• Enck P, Zimmermann K, Menke G, Klosterhalfen S. Randomised controlled treatment trial of irritable bowel syndrome with a probiotic E-coli preparation (DSM17252) compared to placebo. Z Gastroenterol. 2009;47:209–14.
   Google Scholar
• Dolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol. 2009;10:65–69.
   Google Scholar
• Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med. 2009;121(2):119–124.
   Google Scholar
• Williams E, Stimpson J, Wang D, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2009;29:97–103.
   Google Scholar
• Hong KS, Kang HW, Im JP, et al. Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome. Gut and Liver. 2009;3(2):101–107.
   Google Scholar
• Ligaarden SC, Axelsson L, Natersatd K, et al. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomized controlled trial. BMC Gastroenterol. 2010;10:16.
   Google Scholar
• Simrén M, Ohman L, Olsson J, et al. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome: a randomized, double-blind, controlled study. Aliment Pharmacol Ther. 2010;31(2):218–227.
   Google Scholar
• Søndergaard B, Olsson J, Ohlson K, et al. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. Scand J Gastroenterol. 2001;46(6):663–672.
   Google Scholar
• Guglielmetti S, Mora D, Gschwender M, Popp K. Randomized clinical trial. Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life: a double blind, placebo controlled study. Aliment Pharmacol Ther. 2011;33(10):1123–1132.
   Google Scholar
• Choi CH, Jo SY, Park HJ, et al. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome. J Clin Gastroenterol. 2011 [Epub ahead of print].
   Google Scholar
• Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(Suppl 2):1143–1147.
   Google Scholar
• Smith GD, Steinke DT, Kinnear M, et al. A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode
   Google Scholar